Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle Montana’s lawsuit over the company’s fraudulent marketing of Risperdal. According to the lawsuit, J&J and its subsidiaries knew that the drug could cause weight gain, diabetes, and vascular complications, but hid the risks. After approval by the FDA for adult schizophrenia and bipolar disorder in adults, the companies promoted the drug for various conditions in both adults and children.
Of further interest:
Drug firms settle with Montana for $5.9M (Sacramento Bee)